Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Clasificación en acciones #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Precio por acción
$0.1559364
Última sincronización: 2026-09-18
Capitalización bursátil
$195.17K
Cambio (1 día)
6.60%
Cambio (1 año)
-30.91%
País
GB
Comercio Fusion Antibodies plc (FAB)

Categoría

Healthcare
Ingresos de Fusion Antibodies plc (FAB)
Ingresos en Sep 2025 TTM: $2.15M
Según los últimos informes financieros de Fusion Antibodies plc, los ingresos actuales de la empresa (TTM) son $2.15M. En 2024, la empresa obtuvo unos ingresos de $1.43M una disminución en comparación con los ingresos del año 2023, que fueron de $3.58M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Fusion Antibodies plc desde 2013 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 588,305.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 280,545.95%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 103,744.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 733,726.73%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH